Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

NCT07725406 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed or Refractory Multiple Myeloma (MM)

Interventions

DRUG: Lymphodepleting chemotherapy: Cyclophosphamide
DRUG: Lymphodepleting chemotherapy: Bendamustine
DRUG: Lymphodepleting chemotherapy: Fludarabine
OTHER: Lisocabtagene Maraleucel
OTHER: Axicabtagene Ciloleucel
OTHER: Ciltacabtagene Autoleucel
RADIATION: Low-Dose Total Body Irradiation

Sponsor

Weill Medical College of Cornell University